| Name | Title | Contact Details |
|---|---|---|
Justin Gage |
VP, sales, North America | Profile |
Payfare is a global FinTech company offering mobile banking, instant payment and loyalty-reward solutions for today`s workforce. Payfare`s financial technology platform is providing financial inclusion and empowerment to millions of next-generation workers around the globe with a full-service mobile bank account and debit card with instant access to their earnings and relevant cash-back rewards. Payfare was founded in 2015 by fintech entrepreneurs and a senior management team with unparalleled experience in the banking, payment card and financial technology sectors. Payfare is backed by major investors and financial institutions around the world. The company is headquartered in Toronto, Canada. Some of the world`s largest on-demand economy platforms including Uber, Lyft, DoorDash and DiDi trust Payfare to pay their workers.
We are a trusted partner and advisor to executives, founders and funders – bringing strategic and tactical knowledge, expertise and tools that help them solve problems, overcome challenges and reclaim time. We provide a tailored suite of cross-functional services designed to empower and enable brands to grow, drive revenue, operate with ease and transform company culture.
At BRA, we seek to raise the bar by showing our communities the attentiveness that they deserve. Our attorneys are always willing to attend a meeting or take a call, usually free of charge. In fact, property managers and board members have our partners personal cell phone numbers should a need arise after hours. We make certain to provide the same high level of service to all our associations, whether their units are numbered in the twenties or the thousands.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.